Thanks to the tireless efforts of the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS), the US FDA is clearing the way for ten clinics around the United States to treat PTSD patients with MDMA. It's likely that the FDA will grant full approval for the therapy in 2020, reports New Atlas. From the article:
MAPS has previously hypothesized thousands of psychedelic-assisted psychotherapy clinics will open up across the United States. In the near future these clinics may not only administer MDMA for PTSD but also psilocybin, which is currently proving promising for a variety of conditions, including major depression.
The FDA approval for Expanded Access is yet another validation of MDMA-assisted psychotherapy’s safety and efficacy following extraordinarily positive early clinical trial results. Current Phase 3 trials are set to run until 2021 and complete market approval could come as early as 2022.
Our IP Address: